City of Dublin, Ohio, USA
Economic Development Agreements presented to City Council
(Dublin, Ohio) – At the August 12 Dublin City Council meeting four economic development agreements are on the agenda that will create 100 new jobs, retain 65 jobs and expand two existing Dublin businesses.
Agenda – First Readings
Decillion Healthcare LLC, a wholesale specialty and infusion pharmacy, providing comprehensive, cost-effective pharmaceutical and home care solutions, is opening an office and laboratory in Dublin with a plan to create 22 pharmaceutical positions by 2018. The proposed economic development agreement includes a seven-year performance incentive (2014-2020) of 12% for a 10-year lease, valued at $21,000. If approved by Council, Decillion Healthcare has plans to lease 9,000 square feet of office and lab space in the Blazer Research District by October 1, 2013.
ProspeX, LLC, a business services training and lead generation company currently located at 7001 Post Road, recently purchased by Ohio University, is seeking to retain 25 jobs and create 27 new jobs. The proposed economic development agreement includes a three-year performance incentive of 15% on new withholdings, which is capped at $15,500 for the term of the agreement. ProspeX must commit to a minimum five-year lease agreement for a building located in Dublin.
Council will vote on the proposed agreements at the August 26 Council meeting.
Agenda – Second Readings
Navidea Biopharmaceuticals seeks an expansion which includes the addition of 20 new jobs and additional corporate office space in Dublin. The economic development agreement proposed to Navidea includes a five-year, 10% performance incentive on 2014-2018 withholdings collected, capped at $92,000 for the retention of 40 full-time jobs and the creation of 20 new full-time jobs by the end of 2019. Navidea must also commit to a minimum seven year lease agreement for a building located in Dublin.
Navidea Biopharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative precision diagnostic agents for those impacted by cancer and Alzheimer’s disease. In March 2013, Navidea’s Lymphoseek® radiopharmaceutical agent received US FDA approval for use in lymphatic mapping procedures to assist in the localization of lymph nodes draining primary tumors for patients with breast cancer or melanoma.
Persistent Systems, a global software product development company based in India with U.S. headquarters in California, has plans to open a Midwest regional office in Dublin. The company received approval from the State of Ohio Tax Credit Authority on June 24, 2013 for a 45% tax credit for seven years tied to the creation of 30 new IT jobs.
The proposed economic development agreement to Persistent Systems includes a four-year performance incentive of 15% for a five-year lease, valued at $26,000. The company plans to select its Dublin office location by August 1, 2013.
Council will vote on both EDAs at the August 12 meeting.
For more information on the proposed EDAs and full ordinances – go to: http://dublinohiousa.gov/council-meetings/council-agenda-monday-august-12-2013/
For more information, contact:
About the City of Dublin, Ohio USA
Dublin, Ohio, the city that’s “greener,” offers residents and corporate citizens responsive government services, attractive housing, superior public education, direct regional highway access, 120 miles of underground optical fiber network, abundant park space and a dynamic community life. Located just minutes from Ohio’s capital city of Columbus, Dublin is a desirable place for business, raising a family or enjoying professional sporting events and renowned attractions. More information about the City of Dublin at www.dublinohiousa.gov